Colorectal cancer — cancer of the colon (large intestine) and rectum — is the third most commonly diagnosed cancer in South Africa across both sexes. It spans a wide treatment and cost range, from curative surgery for early-stage disease to complex multimodal treatment for metastatic cases. Understanding your medical aid obligations and costs is essential to navigating a colorectal cancer diagnosis.
What Is Colorectal Cancer?
Colorectal cancer develops from polyps in the inner lining of the colon or rectum. It is staged I–IV based on depth of invasion and spread. Treatment, prognosis, and cost differ substantially by stage:
- Stage I: Cancer confined to inner layers; curative surgery; excellent prognosis.
- Stage II: Cancer through bowel wall but not lymph nodes; surgery ± adjuvant chemotherapy.
- Stage III: Cancer in lymph nodes; surgery + adjuvant FOLFOX/CAPOX chemotherapy.
- Stage IV: Metastatic spread (commonly liver, lungs); surgery of primary + systemic therapy; palliative intent in most cases.
Rectal cancer specifically may require preoperative radiation ± chemotherapy (chemoradiation) before surgery.
PMB Coverage in South Africa
Colorectal cancer is covered under the Prescribed Minimum Benefits as a Level 1 oncological condition. Your medical aid is legally obligated to fund diagnosis, surgical resection, adjuvant chemotherapy, and radiation therapy (where clinically indicated).
Key PMB coverage points: - Surgical resection of the primary tumour: funded as PMB. - Adjuvant FOLFOX or CAPOX chemotherapy: funded as PMB minimum standard. - Radiation therapy (rectal cancer): funded as PMB. - Bevacizumab (anti-VEGF) and pembrolizumab (immunotherapy) are NOT PMB minimum standard in most SA scheme interpretations — both typically require exceptional-needs authorisation.
Treatment Pathway
Stage I–II (localised): Colectomy or low anterior resection (LAR) / abdominoperineal resection (APR) for rectal cancer → surveillance. Stage II may receive adjuvant chemotherapy if high-risk features are present.
Stage III (node-positive): Surgical resection → adjuvant chemotherapy (6 months of FOLFOX: folinic acid + 5-fluorouracil + oxaliplatin, or CAPOX: capecitabine + oxaliplatin).
Stage IV (metastatic): Systemic chemotherapy (FOLFOX/CAPOX) with or without targeted therapy: - KRAS/NRAS wild-type: May add anti-VEGF (bevacizumab) or anti-EGFR (cetuximab). - MSI-H/dMMR (~15% of cases): Pembrolizumab (Keytruda) — first-line standard in this subgroup internationally; exceptional-needs in SA. - KRAS mutant (most cases): Anti-VEGF only; no anti-EGFR benefit.
Liver metastasectomy (surgical removal of liver metastases) can be curative in selected patients and is a high-cost surgical procedure.
Rectal cancer specifically: Neoadjuvant chemoradiation before surgery in many Stage II–III cases. Robotic or laparoscopic total mesorectal excision (TME) preferred; some schemes fund open rates only.
Biomarker Testing: Critical for Treatment Decisions
Colorectal cancer requires molecular testing before systemic treatment:
- KRAS/NRAS/BRAF mutation testing: Mandatory before anti-EGFR therapy. Cost: R3,000–R8,000. Not always PMB-funded; schemes vary.
- MSI (microsatellite instability) / MMR (mismatch repair) testing: Required before pembrolizumab consideration. Cost: R3,000–R6,000. Funding varies.
- HER2 amplification testing (in later lines): Emerging; not routinely funded.
If these tests are not funded, patients pay out of pocket. They cannot be deferred — the results directly determine treatment eligibility.
Medication Costs
Costs are estimated; SAHPRA SEP verification pending.
| Medication | Class | Estimated Monthly Cost |
|---|---|---|
| Capecitabine (Xeloda) | Oral fluoropyrimidine | R8,000–R10,000 |
| Oxaliplatin | Platinum chemotherapy | R10,000–R14,000 |
| 5-Fluorouracil (5-FU) | Pyrimidine analogue | R4,000–R5,000 |
| Bevacizumab (Avastin) | Anti-VEGF mAb | R22,000–R28,000 |
| Pembrolizumab (Keytruda) | PD-1 checkpoint inhibitor | R50,000–R60,000 |
Annual Cost Estimates
| Scenario | Estimated Annual Cost |
|---|---|
| Stage I–II, surgery only | R40,000 – R100,000 |
| Stage III, surgery + FOLFOX/CAPOX | R120,000 – R220,000 |
| Stage IV, FOLFOX + bevacizumab | R250,000 – R400,000 |
| Stage IV MSI-H, pembrolizumab | R450,000 – R650,000+ |
The Oncology Sub-Limit: The Critical Number
As with all solid tumour oncology, the oncology sub-limit on your plan is the most important figure for cost planning. For Stage I surgery-only cases, most plans are adequate. For metastatic disease requiring bevacizumab or pembrolizumab, a sub-limit of R250,000 is quickly consumed.
The additional risk in colorectal cancer is that metastatic disease often continues as a chronic, ongoing treatment. Unlike a discrete surgery event, chemotherapy + bevacizumab may continue for 12+ months, consuming the sub-limit each year.
Gap Cover and the Overall Payment Limit
Colorectal cancer generates shortfalls at multiple points:
- Colorectal surgeon: One of the highest-billing surgical specialities in SA; shortfall on major resection can reach R30,000–R70,000.
- Medical oncologist: Ongoing chemotherapy consultations and infusion fees.
- Radiation oncologist: If neoadjuvant chemoradiation for rectal cancer.
- Hepatobiliary surgeon: If liver metastasectomy is performed.
- Anaesthesiologist: At each surgical procedure.
The gap cover OPL (~R220,000/year) can be exhausted in a high-complexity case combining surgery, chemotherapy, and liver resection within a single benefit year.
Stoma (Colostomy/Ileostomy) Management
Some colorectal resections result in a permanent or temporary stoma (a surgically created opening in the abdominal wall). Stoma management involves ongoing consumables (bags, flanges, adhesive products). These costs are typically R1,500–R3,500/month.
Medical aid coverage of stoma appliances varies significantly by plan. Some plans include these as a chronic benefit; others classify them as external medical items with a separate limit. Verify your plan's stoma coverage explicitly.
Talk to Eldon
See which plans pay for colorectal cancer cover →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).